Pharmerit International, York, UK.
Merck Sharp & Dohme Limited, Maidenhead, UK.
BMC Public Health. 2020 Apr 6;20(1):453. doi: 10.1186/s12889-020-08545-4.
Human papillomavirus (HPV) infection is a pre-requisite for cervical cancer, which represents the third most common cancer among women worldwide. A causal relationship also exists between HPV and cancer in other areas of the female reproductive system including the vagina and vulva. Whilst the incidence of vaginal cancer in the UK has remained relatively stable over the past 25 years, vulval cancer rates are increasing. A body of literature exists on the epidemiology and aetiology of vaginal and vulval cancer, but little is known about the economic burden. The objective of this study was to quantify the costs of treating these cancers on the National Health Service (NHS) in England.
Inpatient and outpatient episodes were derived from Hospital Episode Statistics (HES). Health Resource Group (HRG) tariffs and National Reference Costs were used to estimate the cost of treating pre-cancerous and invasive vaginal and vulval lesions in England.
The study showed that for the 5 years from 2009/2010 to 2014/2015 the total cost associated with pre-cancerous and invasive vaginal and vulval lesions was over £14 million per year on average (95% of which was attributed to inpatient costs). Vulval cancer accounted for the largest proportion; an estimated 60% of the total cost (£8.82 million). On average 4316 patients per year in England were admitted to hospital and 912 patients attended outpatient settings for pre-cancerous and invasive disease of the vagina and vulva.
The results indicate that vaginal and vulval cancer cost the English health care system over £14 million per year. Given the causal role of HPV in a proportion of these cancers, preventative measures such as the national HPV immunisation programme have the potential to reduce the economic burden. To ensure optimal use of NHS resources, it is important that future economic evaluations of such preventative measures consider the full burden of HPV related disease.
人乳头瘤病毒(HPV)感染是宫颈癌的前提,宫颈癌是全世界女性中第三常见的癌症。HPV 与女性生殖系统其他部位的癌症也存在因果关系,包括阴道和外阴。尽管在过去的 25 年中,英国阴道癌的发病率保持相对稳定,但外阴癌的发病率正在上升。关于阴道和外阴癌的流行病学和病因学有大量文献,但对其经济负担知之甚少。本研究的目的是量化英国国家医疗服务体系(NHS)治疗这些癌症的成本。
住院和门诊病例来源于医院病例统计(HES)。使用卫生资源组(HRG)关税和国家参考成本来估计在英格兰治疗癌前和侵袭性阴道和外阴病变的成本。
研究表明,在 2009/2010 年至 2014/2015 年的 5 年中,与癌前和侵袭性阴道和外阴病变相关的总成本平均每年超过 1400 万英镑(其中 95%归因于住院费用)。外阴癌占比最大;估计总成本的 60%(882 万英镑)。英格兰平均每年有 4316 名患者住院,912 名患者因阴道和外阴的癌前和侵袭性疾病在门诊就诊。
结果表明,阴道和外阴癌每年给英国医疗保健系统带来超过 1400 万英镑的成本。鉴于 HPV 在这些癌症中的部分因果作用,预防措施,如国家 HPV 免疫计划,有可能减轻经济负担。为确保 NHS 资源的最佳利用,未来对这些预防措施的经济评估应考虑 HPV 相关疾病的全部负担。